Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pirfenidone for Pulmonary Fibrosis in Hermansky-Pudlak Syndrome
NCT00001596Phase 2Completed
- Start
- Sep 2005
- Primary completion
- Sep 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Hermansky-Pudlak syndrome (HPS) and pulmonary fibrosis (PF) comparing Pirfenidone with Placebo (2 arms). Primary endpoint: Change in Forced Vital Capacity at 36 months. Started Sep 2005; status: completed.
02
Drugs
pirfenidone
03
Conditions
Hermansky-Pudlak syndrome (HPS)pulmonary fibrosis (PF)
Beyond the preview
Go deeper on NCT00001596.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00001596.